| Active substance | Idelalisib |
| Holder | Gilead Sciences Benelux |
| Status | Closed |
| Indication | follicular lymphoma (FL) refractory to two prior lines of therapy |
| Public documents | Approbation |
| Information for the patient | |
| Informed consent | |
| Last update | 10/12/2015 |
Zydelig®
Last updated on 16/12/2020